A Novel Phenylchromane Derivative Increases the Rate of Glucose Uptake in L6 Myotubes and Augments Insulin Secretion from Pancreatic Beta-Cells by Activating AMPK
作者:Naomi Rozentul、Yosef Avrahami、Moran Shubely、Laura Levy、Anna Munder、Guy Cohen、Erol Cerasi、Shlomo Sasson、Arie Gruzman
DOI:10.1007/s11095-017-2271-7
日期:2017.12
A series of novel polycyclic aromatic compounds that augment the rate of glucose uptake in L6 myotubes and increase glucose-stimulated insulin secretion from beta-cells were synthesized. Designing these molecules, we have aimed at the two main pathogenic mechanisms of T2D, deficient insulin secretion and diminished glucose clearance. The ultimate purpose of this work was to create a novel antidiabetic drug candidate with bi-functional mode of action. All presented compounds were synthesized, and characterized in house. INS-1E cells and L6 myoblasts were used for the experiments. The rate of glucose uptake, mechanism of action, level of insulin secretion and the druggability of the lead compound were studied. The lead compound (6-(1,3-dithiepan-2-yl)-2-phenylchromane), dose- and time-dependently at the low μM range increased the rate of glucose uptake in L6 myotubes and insulin secretion in INS-1E cells. The compound exerted its effects through the activation of the LKB1 (Liver Kinase B1)-AMPK pathway. In vitro metabolic parameters of this lead compound exhibited good druggability. We anticipate that bi-functionality (increased rate of glucose uptake and augmented insulin secretion) will allow the lead compound to be a starting point for the development of a novel class of antidiabetic drugs.
一系列新型多环芳香化合物被合成,这些化合物能够提高L6肌管中葡萄糖摄取速率,并增加β细胞中葡萄糖刺激的胰岛素分泌。在设计这些分子时,我们针对T2D的两个主要发病机制:胰岛素分泌不足和葡萄糖清除率降低。这项工作的最终目的是创造一种具有双重作用模式的新型抗糖尿病候选药物。所有介绍的化合物均在内部合成和表征。实验使用了INS-1E细胞和L6肌细胞。研究了葡萄糖摄取速率、作用机制、胰岛素分泌水平及先导化合物的成药性。先导化合物(6-(1,3-二硫杂环戊烷-2-基)-2-苯基色满)在低微摩尔范围内,剂量和时间依赖性地增加L6肌管中葡萄糖摄取速率及INS-1E细胞中胰岛素分泌。该化合物通过激活LKB1(肝激酶B1)-AMPK途径发挥作用。体外代谢参数显示该先导化合物具有良好的成药性。我们预期其双重功能(增加葡萄糖摄取速率和增强胰岛素分泌)将使该先导化合物成为开发新型抗糖尿病药物的起点。